Oncology Analytics senior vice president Laura Bobolt discusses the new indication for Trodelvy and other matters.
Oncology Analytics is a data analytics and technology-enabled services company that collaborates with health plans, healthcare providers and patients with innovative solutions developed for oncology care.
Laura R. Bobolts, Pharm.D., BCOP, SVP, Clinical Strategy and Growth for Oncology Analytics discussed the important role that technology and evidence-based medicine play in urothelial cancer management.
What is your role at Oncology Analytics?
I serve as a clinical subject matter expert, demonstrating the real, everyday value of our extensive oncology expertise and patient first approach to improve cancer care for a health plan’s members. I evaluate claims data, combined with utilization management data at the regimen level, to surface actionable clinical insights and discuss the rapidly changing oncology treatment landscape with our health plan partners. My day also includes supporting our brilliant board-certified oncology pharmacists and oncology certified nurses to ensure they have what they need to extend authorization for the latest cost-effective, high quality cancer treatment regimens and associated supportive care medications.
With unmet needs for locally advanced or metastatic urothelial cancer, what do you feel are some of the benefits of this new indication for Trodelvy?
This recent approval of Trodelvy expands our targeted therapy options for advanced/metastatic urothelial carcinoma, more commonly third-line or later. We are seeing a rise in targeted therapeutic options, moving away from traditional chemotherapy, in later line treatment of palliative cancers—this approval continues to support that trend.
What type of programs does Oncology Analytics provide for urothelial cancer treatments?
Oncology Analytics provides an electronic portal to expedite the prior authorization of cancer treatments with a patient-centric, evidence-based medicine focus. While National Comprehensive Cancer Network lists a myriad of treatment options, we go the extra mile to evaluate if the planned treatment is the best fit to afford the cancer patient the best outcomes possible based on safety and efficacy data, as well as the patient-specific disease characteristics, including molecular biomarkers, performance status, prior treatments, appropriate sequencing of therapies, and the patient’s unique treatment needs.We evaluate therapy based on efficacy first and foremost, followed by toxicity and affordability, leveraging a myriad of coverage determination resources, including primary scientific literature for eligible off-label coverage.